Background: This study aimed to investigate if treatment response could retrospectively be related to inflammatory or axonal pathology as measured by plasma surrogate markers. Methods: In this I-year observational study 30 multiple sclerosis (MS) patients with relapsing-remitting disease were treated with intramuscular IFN&beta;-Ia or subcutaneous IFN&beta;-1b. Responders and nonresponders were defined according to clinical and magnetic resonance imaging criteria. The control group consisted of 14 healthy subjects. Plasma levels of surrogate markers for inflammation (nitric oxide metabolites (NO x )), astrocytic activation (S100B) and axonal damage (NfH SM135 ) were measured using standard assays. Results: There were 1 1 nonresponders and 19 responders to IFN&beta; treatment. Median S100B levels were elevated in a higher proportion of treatment responders (63%, 42.9 pg/mL) compared to nonresponders (18%, 11.7 pg/mL, P < 0.05, Fisher's exact test) and controls (0%, 2 pg/mL, P < 0.001). Levels of NOx were found to be more frequently elevated in nonresponders (72%, 39 &mu;M) compared to healthy controls (0%, 37&mu;M, P < 0.05). Levels of NfH SM135 were more frequently elevated in responders (58%, 300 pg/mL, P < 0.001) and nonresponders (72%, 500 pg/mL, P < 0.001) compared to controls (0%, 4.5 pg/mL). Conclusion: Patients with relapsing-remitting MS who had surrogate marker supported evidence for astrocytic activation responded more frequently to treatment with IFN&beta;. Multiple Sclerosis (2004) 10, [281][282][283] 
Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis Introduction Characterizing responders and nonresponders to treatment in multiple sclerosis (MS) is of relevance for understanding disease progression and selecting effective drug treatment strategies. MS is a heterogeneous disease' and it was suggested that the heterogeneity of treatment response could be related to the underlying pathology.' Particularly inflammation has been associated with relapses, and relapse frequency early on is related to disease progression. The proven benefit common to all currently recommended treatments is a reduction in the rate of clinical relapse, which has been associated to a transient slowing of disease progression.~ During the early phase of MS active disease has been related to elevated levels of S100B4 and the nitric oxide metabolites nitrate and nitrite (NOX). 5 5 The hypothesis underlying this study was that patients who responded to IFN(3 treatment would be different from nonresponders with regard to their profile of plasma inflammatory (NOX), astrocytic activation (S100B) and axonal (NfHSMI:35) markers.
Materials and methods

Patients
Thirty patients with relapsing-remitting multiple sclerosis (RRMS)6 were included in this cross-sectional study.
All patients were treated with IFNP and recruited from the MS specialist clinic at the Toulouse Purpan H6pital between March 2000 and November 2001. The control group consisted of 14 healthy volunteers. All plasma samples were obtained by antecubital venepuncture at the last clinical assessment. Samples were coded and stored at -70°C until analysis. Approval for the study was obtained from the local Ethics Committees. Written informed consent was obtained from each subject.
Clinical assessment All patients were assessed by two experienced neurologists (DB, MC). The Expanded Disability Status Scale score (EDSS) and the yearly relapse frequency prior to sampling were recorded. &dagger; Both authors contributed equally to the study.
It was decided to declare treatment failure based on clinical and MRI criteria (when available). Patients who suffered from at least two clinical relapses associated with at least one gadolinium-enhancing lesion on Tl magnetic resonance imaging (MRI) performed at least one month after steroid treatment ('active MRI'), or patients who progressed by over 1 point on the EDSS associated with an active MRI.
Assays
Plasma levels of S100B, NO,, and NfHsMI35 were measured using standard assays as described previ OUSIY.7-'o The cutoff value for abnormal levels of these biomarkers were defined as the top value of the control group.
Statistical analysis
All statistical analyses and graphs were done using SAS software (V8.2, SAS Institute, Inc., Cary, NC, USA).
Because of the non-Gaussian distribution all data is presented as the median and interquartile range (IQR). The box (median and 25%-75% cumulative frequency) and whisker (1%-100% cumulative frequency) are shown in the graphs. Because of the small sample size Fisher's exact test was used for comparison of proportions of patients. The linear relationship between continuous variables was evaluated using the nonparametric Spearman correlation coefficient (a = 0.05).
Results
--
The baseline characteristics of the MS patients are summarized in Table 1 . According to our definition there were 11 responders and 19 nonresponders. Patients with MS were significantly younger than the control patients and there were more females. There were no significant differences between responders and nonresponders with regard to the EDSS. The choice of the generic drug was not related to treatment response.
The plasma levels for S100B, NOX and NfHSMI35 (median, range) are summarized in Table 1 . The cutoff levels were determined as the top value from the control group (S100B = 33 pg/mL, NO, = 44 11M, NfHsMI35 = 250 pg/mL).
In all nonresponders MRI was performed. Although a subgroup of responders (n = 16) received an MRI brain scan. However the timing of MRI brain scan to relapse and plasma sampling was not rigorous.
A significantly higher proportion of responders (63%) but not of nonresponders (18%) had S100B levels above cutoff compared to controls (P = 0.021). The individual values are shown in Figure 1 . There were two outliers with plasma S100B levels over 300 pg/mL among the responders (Figure 1 ). Removal of these two outliers did not alter statistical significance (P = 0.034, Fisher's exact test). A significant proportion of nonresponders (45%) had NOx levels above cutoff. Also a significant proportion of responders (58%) and nonresponders (72%) had NfHSMI35 levels above cutoff. There was no significant difference Figure 1 (A) Plasma S100B (pglmL) levels in normal controls, treatment non-responders and treatment responders. The dotted horizontal line indicates the cutoff of 33 pglml (100% cumulative frequency of the control group). The relapse frequency is given in number of relapses per year. The age and disease duration are given in years. Levels of plasma S100B, NOX, NfHsMI3S median (range) in patients based on clinical criteria of treatment failure. Statistical comparisons are indicated in the following order: control versus nonresponder; controls versus responder; nonresponder versus responder. NS = not significant. comparing proportions of responders and nonresponders for either NO,, or NfHsMI35.
There was no correlation between age, EDSS, relapse frequency and either S100B, NO,, or NfHsMI35 for any of the subgroups.
Discussion
This study found higher plasma levels S100B, NOx and NfHsMI35 in patients with MS than in healthy controls. In treatment responders the median S100B levels were over 3-fold higher than in nonresponders.
We and others previously related elevated CSF S100B to acute disease activity in MS.4 It is therefore difficult to understand if not paradoxical that treatment responders should have higher plasma S100B levels. A major criticism of this study is the retrospective, cross-sectional design and the lack of MRI data in some of the patients. However in a longitudinal study on serum S100B in primary progressive MS patients from a clinically negative phase II trial we found similar levels in the nonresponders (E Lim, unpublished data).
The current understanding is that IFN(3 reduces disease activity by exerting immunomodulatory properties. However in vivo and in vitro data shows upregulation of proinflammatory factors during IFNP treatment.' On the background that inflammation has been related to protective and destructive mechanisms,12 it can be speculated that these properties might be related in degree to a spectrum of severity. Severe inflammation, blood-brain barrier (BBB) disruption and neutrophil invasion were all related to tissue destruction. 13 Indeed there was a trend for higher NfHsMI35 levels in nonresponders. Previously we have shown that particularly the combination of inflammation with axonal damage indicated poorer prognosis.'4 However low grade inflammation orchestrated by the macrophage and microglial network could be neuroprotective. In vitro data supports this notion in that nanomolar levels of S100B are neurotrophic. 15 This suggests that moderately elevated S100B levels might be beneficial in the context of IFN(3 effects on BBB integrity and inhibition of more severe steps of inflammatory activity such as T-cell invasion and subsequent neuroaxonal degeneration.
